1. Introduction {#sec1-jcm-08-01722}
===============

Nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers are common in old patients, patients on multiple medications, patients with comorbidities, *Helicobacter pylori (H. pylori)* infection, and history of peptic ulcer \[[@B1-jcm-08-01722],[@B2-jcm-08-01722]\]. A study has reported that 6.4%--11.8% of patients who were prescribed NSAIDs developed peptic ulcer disease (PUD), particularly NSAID-naïve patients (odds ratio (OR) = 0.26, 95% Confidence interval (CI): 0.14--0.49) compared with long term users of NSAIDs (OR = 0.74, 95% CI: 0.46--1.20) \[[@B3-jcm-08-01722]\]. Vergara et al. added that *H. pylori* eradication therapy alone had no significant clinical benefit in chronic users in their study (OR = 0.95, 95%CI: 0.53--1.72) \[[@B4-jcm-08-01722]\].

Both Asia-Pacific and American College of Gastroenterology Clinical guidelines state that patients with H. pylori infection who have used NSAIDs are at an increased risk for developing PUD \[[@B5-jcm-08-01722],[@B6-jcm-08-01722]\]. Hence, patients with PUD who have used NSAIDs for primary prevention should be tested and treated for *H. pylori* infection. Regarding *H. pylori* eradication as a secondary preventive measure for PUD in NSAID users, Chan et al. observed that treatment with proton pump inhibitors (PPIs) was more beneficial in reducing recurrent bleeding over 6 months than *H. pylori* eradication alone. In clinical practice, it is important to prescribe concomitant PPIs for all NSAID users who have a medical record of PUD with complications \[[@B7-jcm-08-01722]\].

It is well understood that by eliminating *H. pylori* for both primary and secondary prophylaxis effectively decrease ulcer risk among naïve NSAID users. However, it is not evidenced whether the success in killing of these bacteria can help in reducing the recurrence of peptic ulcers in long-term users of NSAIDs, particularly those with a medical record of PUD \[[@B8-jcm-08-01722],[@B9-jcm-08-01722]\]. Importantly, very few studies have examined whether the eradication therapy affects the recurrence of PUD in patients receiving a high cumulative defined daily dose (cDDDs) of NSAIDs. Therefore, we used the Taiwan National Health Insurance Research database (NHIRD) in an attempt to clarify the impact of cumulative dosage of NSAIDs on recurrent peptic ulcers among chronic users after H. pylori eradication.

2. Methods {#sec2-jcm-08-01722}
==========

2.1. Study Population {#sec2dot1-jcm-08-01722}
---------------------

This study was reviewed and permitted by the Ethics Committee of Chang Gung Memorial Hospital in Taiwan (Institutional review board 201800321B0). Data required for the study were collected from the claims data recorded in Taiwan's NHIRD, an anonymized dataset of one million randomly selected individuals from 1997 to 2013. Patients with original admission record of a major diagnosis of PUD or two outpatient visit PUD diagnoses \>28 days apart (International Classification of Diseases, 9th Revision codes: 531x, 532x, 533x, and 534x) were selected. Patients with PUD (*n* = 203,407) were enrolled as shown in [Figure 1](#jcm-08-01722-f001){ref-type="fig"}. Eventually, 27,920 patients were enrolled for analysis after excluding 175,487 patients aged \<18 years or patients who met PUD diagnostic criteria within 365 days before the index date; those who received NSAIDs, aspirin, PPIs, or H2 blockers within 180 days before the index date; those who received *H. pylori* eradication therapy before the index date; those who had bleeding varices; those with any malignancy who developed the disease before and after the index date; and those who developed serious infections \[[@B10-jcm-08-01722],[@B11-jcm-08-01722]\] and suffered major traumas \[[@B12-jcm-08-01722],[@B13-jcm-08-01722]\] after PUD diagnosis.

A case-control study design of NSAID exposure and recurrent PUD was used in the PUD cohort. Recurrent PUD was defined as endoscopically proven PUD occurring 180 days' post-index date (the first date of PUD diagnosis). The incident recurrent PUD risk was evaluated during 3 years of follow-up. Patients who developed recurrent PUD during the follow-up period were classified into the case group; patients without recurrent PUD (controls) were randomly selected by matching age/gender frequencies with patients in the case group in a 1:1 ratio. To avoid immortal time bias, the follow-up duration for patients in the case group was applied to the randomly selected matched controls. Immortal time refers to a span of time in the observation of the control group of patients during which they could not have developed recurrent PUD or could not have died. Following the follow-up time-matched controls, the misclassification of NSAIDs and relevant risk factor exposure between case and control groups could be avoided. Finally, two groups of patients were analyzed: recurrent PUD (*n* = 1185) and non-recurrent PUD (controls, *n* = 4395).

2.2. NSAIDs Exposure {#sec2dot2-jcm-08-01722}
--------------------

A specific term known as the defined daily dose (DDD) has been suggested by the World Health Organization as a unit for quantifying a prescribed dose of medication anticipating the average prescription dose per day in adult population \[[@B14-jcm-08-01722]\]. This allowed us to compare any class of NSAIDs on similar reference line: (sum of drug used)/(amount of drug in a DDD) = number of DDDs. cDDD refers to the total bare dose, assessed as the total of the allocated DDD of any NSAIDs, to equate the risk of PUD among a cohort. To further recognize the possible influence of the dose effect, we classified the NSAID dose into four sets in each group (0, ≤28, 29--83, and ≥84 cDDDs). Patients were considered as not taking any NSAIDs if the cDDD was zero.

2.3. Other Ulcerogenic Agents and Potential Confounders {#sec2dot3-jcm-08-01722}
-------------------------------------------------------

We obtained the complete data from the database, which included the first and last prescription dates of all the ulcerogenic medications in between the follow-up dates during the follow-up period after the index hospitalization. These medications were aspirin, clopidogrel, dipyridamole, warfarin, ticlopidine, cilostazol, and Ginkgo biloba (cerenin^®^). Recorded comorbidities were simultaneously analyzed among those with a history of coronary artery disease, cerebrovascular accidents, hypertensive disease, diabetes mellitus, chronic obstructive lung disease, advanced chronic liver disease which included liver cirrhosis, and hyperlipidemia. Charlson comorbidity index was calculated as a potential confounding risk \[[@B15-jcm-08-01722]\].

2.4. Helicobacter Pylori Therapy and Eradication {#sec2dot4-jcm-08-01722}
------------------------------------------------

In the present study, we defined H. pylori-associated PUD as the use of any recorded *H. pylori* eradication therapy medications, such as a combination medication prescription of 7--14 days of any of the following antibiotics in the same medication order such as clarithromycin or metronidazole and amoxicillin or tetracycline, in addition to a PPIs or H2 blockers (H2RAs) \[[@B16-jcm-08-01722],[@B17-jcm-08-01722],[@B18-jcm-08-01722]\]. Summary of *H. pylori* treatment regimens used in this study were summarized in [Table S1](#app1-jcm-08-01722){ref-type="app"}.

2.5. Statistical Analysis {#sec2dot5-jcm-08-01722}
-------------------------

All statistical analyses were completed by using software package SAS version 9.3 (SAS Institute Inc., Cary, NC, USA, 2013) with descriptive measurements for all variables. Continuous statistics were expressed as mean (standard deviation) and median (interquartile range). Categorical statistics were expressed as actual frequencies and percentages. Unpaired Student's t-test and chi-square analysis of contingency tables for continuous and insignificant variables were applied to compare baseline characteristics. Logistic regression modeling was used to fix the potentially relevant issues influencing the outcome with modifications in the multivariate analysis. A *p*-value \< 0.05 was considered significant.

3. Results {#sec3-jcm-08-01722}
==========

Among the study patients, there were 1185 patients with recurrent PUD (case group) and 4395 patients without recurrent PUD (control group). After matching for age/gender frequencies and the length of follow-up time in a 1:1 ratio, the matched case-control groups comprised 1150 patients with recurrent PUD and 1150 patients without recurrent PUD within 3 years of follow-up (mean follow-up time: 20.65 (8.77) months).

[Table 1](#jcm-08-01722-t001){ref-type="table"} presents a comparison of patient characteristics between the case and control groups. The proportion of NSAID users was higher in the case (recurrent PUD) group than in the control group in both primary (74.85% versus 63.32%; *p* \< 0.0001) and matched (75.30% versus 69.74%; *p* = 0.0028) cohorts. In the matched case--control group, *H. pylori* eradication therapy (8.61% versus 3.48%; *p* \< 0.0001), concomitant PPI users (22.43% versus 17.22%; *p* = 0.0017); and H2RA users (26.87% versus 17.57%; *p* \< 0.0001) were significantly higher in the case (recurrent PUD) group than in the control group.

Multivariate analysis ([Table 2](#jcm-08-01722-t002){ref-type="table"}) showed that the independent risk factors for recurrent PUD were patients using NSAIDs (aOR: 1.34; *p* = 0.0040), those with *H. pylori* eradication (aOR: 2.73; *p* \< 0.0001), and those with concomitant H2RA (aOR: 1.85; *p* \< 0.0001) and anti-coagulant (aOR: 4.21, *p* = 0.0242) use, but not with PPI use (aOR: 1.13; *p* = 0.3022). The risk for recurrent PUD increased with the increasing NSAID dosage (aOR: 1.24, *p* = 0.0430; aOR: 1.52, *p* = 0.0043; and aOR: 1.67, *p* = 0.0179 in the groups of ≤28, 29--83, and ≥84 cDDDs, respectively). The use of diclofenac, piroxicam, and sulindac was a significant risk factor for recurrent PUD (aOR: 1.33, *p* = 0.0042; aOR: 1.59, *p* = 0.0346; and aOR: 1.59, *p* = 0.0367, respectively).

In the subgroup analysis, the risk ratio of recurrent PUD did not increase in NSAID users after *H. pylori* eradication compared with that in non-users (*p* = 0.8490). However, there was a progressively higher risk for recurrent PUD with the increasing doses of NSAIDs without *H. pylori* eradication therapy (aOR: 1.24, *p* = 0.0424; aOR: 1.47, *p* = 0.0074; and aOR: 1.64, *p* = 0.0152 in the groups of ≤28, 29--83, and ≥84 cDDDs, respectively) ([Table 3](#jcm-08-01722-t003){ref-type="table"}).

4. Discussion {#sec4-jcm-08-01722}
=============

According to published guidelines, *H. pylori* eradication therapy alone is suboptimal for the secondary prophylaxis of ulcers or PUD bleeding in patients who have continuously been prescribed NSAIDs \[[@B5-jcm-08-01722],[@B6-jcm-08-01722]\]. Instead, concomitant use of PPIs or switching to cyclooxygenase-2 (COX-2) inhibitors or a combination of COX-2 inhibitors and PPIs is still recommended \[[@B19-jcm-08-01722],[@B20-jcm-08-01722]\]. Furthermore, it was found that the optimal gastrointestinal protection could be achieved by using selective COX-2 inhibitors with PPIs \[[@B21-jcm-08-01722]\]. In this study, the risk of recurrent PUD was high in patients using concomitant H2RAs (aOR: 1.85; *p* \< 0.0001) but not in those using PPIs (aOR: 1.13; *p* = 0.3022). Therefore, the protective efficacy of concomitant PPIs for recurrent PUD is better than that of H2RAs. This result is similar to another database systematic review study \[[@B22-jcm-08-01722]\], but a double-dose H2RA may have considerably more beneficial outcome than PPIs in reducing the risk of duodenal and gastric ulcers (relative risk (RR) = 0.44 and 0.40, respectively).

At the first glance of the initial analysis, *H. pylori* eradication was found to be a factor for recurrent PUD (aOR: 2.73; *p* \< 0.0001). However, in the subgroup analysis, the risk ratio of recurrent PUD did not increase after *H. pylori* eradication in NSAID users compared with that in non-users (*p* = 0.8490). In patients without H. pylori eradication therapy as shown in [Table 3](#jcm-08-01722-t003){ref-type="table"}, there was a progressively higher risk for recurrent PUD with the increasing doses of NSAIDs (aOR: 1.24, *p* = 0.0424; aOR: 1.47, *p* = 0.0074; and aOR: 1.64, *p* = 0.0152 in the groups of ≤28, 29--83, ≥84 cDDDs, respectively). This implied that *H. pylori* eradication therapy decreased the risk of recurrent ulcers during the prolonged NSAID use. Although the eradication alone was suboptimal in reducing recurrent PUD, it was still needed in NSAID users who required prolonged medications. According to some studies in Taiwan \[[@B23-jcm-08-01722],[@B24-jcm-08-01722]\], approximately 53.9% (95% CI, 36.6--71.2) patients with H. pylori infection were not evaluated for *H. pylori* status. In other words, in H. pylori-positive patients without the eradication therapy, the risk of recurrent PUD may increase with the increase in the dosage of NSAIDs used. Our study was similar to the previous population-based studies from Spain \[[@B25-jcm-08-01722],[@B26-jcm-08-01722],[@B27-jcm-08-01722]\], taking into consideration the daily dosage, the RR was 2.79 (95% CI, 2.17--3.58) for the NSAIDs users at low or medium doses compared to 5.36 (95% CI, 4.57--6.29) among those receiving high doses of medications \[[@B28-jcm-08-01722]\]. In real-world clinical practice, poor adherence to guideline recommendations on the issue of the risk of PUD bleeding without prophylactic PPI prescription is common among NSAID users. Even in this national population study, the rate of concomitant PPI use was only 22.45% before matching. In a Turkish population, Dincer et al. reported that only 25% of NSAID users with a previous history of peptic ulcer bleeding received a PPI prophylaxis \[[@B29-jcm-08-01722]\].

The strength of this study was that it was a large sample size population-based case controlled study and quantify the level of drug exposure to the association of recurrent PUD among chronic users after H. pylori eradication by the concept of cDDD. Similarly, it still came across some limitations. First, the number of cases with *H. pylori* infection was low, owing to strict exclusion criteria, and, consequently, not enough to analyze the NSAID dose effect in *H. pylori* eradication group. Another major limitation of our study data retrieved from NHIRD was the lack of anthropometric data and individual status, such as atrophic grades of gastric mucosa, drug compliance, *H. pylori* eradication rate, and antibiotic resistance. This limitation is due to the inherent shortcomings of the administrative database. Drug compliance is an important factor in the assessment of NSAIDs use with gastric bleeding, but compliance to any medications is not available in the database of health insurance system. This was overcome by using the concept of cDDD, which designated the total exposed dosage assessed as the total of allotted DDD of any NSAIDs to compare the risk of PUD among them. Eventually, we were able to analyze cDDD by using the Taiwan NHI program. This was because it was a compulsory, third party payer insurance program, and provides comprehensive health services such as procedures, medications in inpatient, outpatient and emergency department for almost 100% of the Taiwanese. Third, Bytzer et al. reported that low socioeconomic class was a risk factor for peptic ulcer disease \[[@B30-jcm-08-01722]\]. However, urbanization or income levels were not assessed in the present study. Finally, this was a retrospective study rather than a prospective intervention trial, limiting the ability to show cause and effect.

5. Conclusions {#sec5-jcm-08-01722}
==============

The risk of recurrent PUD increases progressively in patients with high cumulative doses of NSAIDs. *H. pylori* eradication therapy could reduce the risk of recurrent PUD among NSAID users who needed prolonged treatment durations. *H. pylori* eradication alone is suboptimal for NSAID users with a medical record of PUD and concomitant PPI treatment is required in such patients.
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jcm-08-01722-t001_Table 1

###### 

Characteristics between patients with and without recurrent peptic ulcer disease.

  Variables                                      Primary Case-Control Group   Matched Case-Control Group                                                                           
  ---------------------------------------------- ---------------------------- ---------------------------- --------------- ---------- -------------- -------------- -------------- ----------
  **Follow up period (months)**                  18.33 ± 10.66                20.47 ± 8.79                 17.75 ± 11.04   \<0.0001   20.65 ± 8.77   20.65 ± 8.77   20.65 ± 8.77   1.0000
  **NSAID use**                                                                                                            \<0.0001                                                0.0028
  DDD = 0                                        1910                         298(25.15)                   1612(36.68)                632            284(24.70)     348(30.26)     
  DDD \> 0                                       3670                         887(74.85)                   2783(63.32)                1668           866(75.30)     802(69.74)     
  **NSAID cDDD group**                                                                                                     \<0.0001                                                0.0156
  DDD = 0                                        1910                         298(25.15)                   1612(36.68)                632            284(24.70)     348(30.26)     
  0 \< DDD ≤ 28                                  2736                         632(53.33)                   2104(47.87)                1203           614(53.39)     589(51.22)     
  28 \< DDD ≤ 84                                 667                          183(15.44)                   484(11.01)                 335            180(15.65)     155(13.48)     
  84 \< DDD                                      267                          72(6.08)                     195(4.44)                  130            72(6.26)       58(5.04)       
  **HP eradication therapy**                     263                          102(8.61)                    161(3.66)       \<0.0001   139            99(8.61)       40(3.48)       \<0.0001
  **Gender**                                                                                                               \<0.0001                                                1.0000
  Female                                         2623                         459(38.73)                   2164(49.24)                912            456(39.65)     456(39.65)     
  Male                                           2957                         726(61.27)                   2231(50.76)                1388           694(60.35)     694(60.35)     
  **Age group (years)**                                                                                                    \<0.0001                                                1.0000
  18--30                                         655                          118(9.96)                    537(12.22)                 224            112(9.74)      112(9.74)      
  31--40                                         900                          193(16.29)                   707(16.09)                 384            192(16.70)     192(16.70)     
  41--50                                         1123                         288(24.30)                   835(19.00)                 566            283(24.61)     283(24.61)     
  51--60                                         1086                         254(21.43)                   832(18.93)                 480            240(20.87)     240(20.87)     
  61--70                                         724                          164(13.84)                   560(12.74)                 310            155(13.48)     155(13.48)     
  \>70                                           1092                         168(14.18)                   924(21.02)                 336            168(14.61)     168(14.61)     
  **Comorbidity**                                                                                                                                                                  
  Acute myocardial infarction                    30                           3(0.25)                      27(0.61)        0.1313     8              3(0.26)        5(0.43)        0.4787
  Congestive heart failure                       111                          5(0.42)                      106(2.41)       \<0.0001   25             5(0.43)        20(1.74)       0.0026
  Peripheral vascular disease                    26                           0(0.00)                      26(0.59)        0.0080     7              0(0.00)        7(0.61)        0.0081
  Cerebral vascular accident                     283                          41(3.46)                     242(5.51)       0.0044     86             40(3.48)       46(4.00)       0.5096
  Dementia                                       69                           8(0.68)                      61(1.39)        0.0488     16             8(0.70)        8(0.70)        1.0000
  Pulmonary disease                              470                          93(7.85)                     377(8.58)       0.4221     184            93(8.09)       91(7.91)       0.8778
  Connective tissue disorder                     29                           7(0.59)                      22(0.50)        0.7017     9              7(0.61)        2(0.17)        0.0949
  Liver disease                                  514                          137(11.56)                   377(8.58)       0.0016     216            127(11.04)     89(7.74)       0.0066
  Diabetes                                       485                          78(6.58)                     407(9.26)       0.0037     169            77(6.70)       92(8.00)       0.2306
  Diabetes complications                         119                          18(1.52)                     101(2.30)       0.0995     35             17(1.48)       18(1.57)       0.8647
  Paraplegia                                     18                           2(0.17)                      16(0.36)        0.2928     5              2(0.17)        3(0.26)        0.6544
  Renal disease                                  188                          35(2.95)                     153(3.48)       0.3716     66             34(2.96)       32(2.78)       0.8027
  Severe liver disease                           25                           2(0.17)                      23(0.52)        0.1048     4              2(0.17)        2(0.17)        1.0000
  HIV                                            4                            0(0.00)                      4(0.09)         0.2989     2              0(0.00)        2(0.17)        0.1571
  Hypertension                                   1073                         205(17.30)                   868(19.75)      0.0575     393            197(17.13)     196(17.04)     0.9558
  Hyperlipidemia                                 455                          80(6.75)                     375(8.53)       0.0467     177            79(6.87)       98(8.52)       0.1372
  **Medication use in the baseline period**                                                                                                                                        
  Antiplatelet                                   236                          44(3.71)                     192(4.37)       0.3197     85             44(3.83)       41(3.57)       0.7402
  Anti-coagulants                                19                           2(0.17)                      17(0.39)        0.2529     4              2(0.17)        2(0.17)        1.0000
  ACEI/ARB                                       519                          105(8.86)                    414(9.42)       0.5565     208            100(8.70)      108(9.39)      0.5608
  SSRIs                                          18                           2(0.17)                      16(0.36)        0.2928     5              2(0.17)        3(0.26)        0.6544
  **Concomitant medications during follow-up**                                                                                                                                     
  PPIs                                           1036                         266(22.45)                   770(17.52)      0.0001     456            258(22.43)     198(17.22)     0.0017
  H2RA                                           1017                         317(26.75)                   700(15.93)      \<0.0001   511            309(26.87)     202(17.57)     \<0.0001
  Antiplatelet                                   560                          129(10.89)                   431(9.81)       0.2724     258            126(10.96)     132(11.48)     0.6918
  Anti-coagulants                                44                           14(1.18)                     30(0.68)        0.0849     20             14(1.22)       6(0.52)        0.0724
  Cerenin^®^                                     40                           9(0.76)                      31(0.71)        0.8445     18             9(0.78)        9(0.78)        1.0000
  Aspirin                                        269                          67(5.65)                     202(4.60)       0.1314     133            64(5.57)       69(6.00)       0.6551
  SSRIs                                          116                          22(1.86)                     94(2.14)        0.5456     50             21(1.83)       29(2.52)       0.2527

Abbreviations: PUD, peptic ulcer disease; NSAIDs, non-steroidal anti-inflammatory drugs; cDDD, cumulative defined daily doses; HP, *Helicobacter pylori*; HIV, human immunodeficiency virus; ACEI/ARB, angiotension-converting enzyme *inhibitor/* angiotension receptor blocker, PPIs, proton pump inhibitors; H2RA, H2 receptor antagonists; Cerenin^®^, Ginkgo biloba leaves extract; SSRIs, selective serotonin reuptake inhibitors; SD (standard deviation).

jcm-08-01722-t002_Table 2

###### 

Factors associated with recurrent PUD occurrence in matched case-control group.

  Variables                                      Matched Case-Control Group                   
  ---------------------------------------------- ---------------------------- --------------- ----------
  **NSAID cDDD group (ref: cDDD = 0)**                                                        
  cDDD ≤ 28                                      1.24                         (1.01--1.52)    0.0430
  28 \< cDDD ≤ 84                                1.52                         (1.14--2.02)    0.0043
  84 \< cDDD                                     1.67                         (1.09--2.56)    0.0179
  HP eradication therapy                         2.73                         (1.80--4.15)    \<0.0001
  **Kinds of NSAIDs**                                                                         
  diclofenac                                     1.33                         (1.09--1.61)    0.0042
  mefenamic acid                                 1.05                         (0.86--1.28)    0.6379
  ibuprofen                                      0.98                         (0.78--1.22)    0.8409
  ketorolac                                      0.95                         (0.73--1.23)    0.7039
  ketoprofen                                     1.27                         (0.90--1.79)    0.1696
  naproxen                                       1.38                         (0.98--1.93)    0.0630
  acemetacin                                     0.86                         (0.61--1.21)    0.3839
  meloxicam                                      1.15                         (0.76--1.76)    0.5045
  celecoxib                                      0.80                         (0.50--1.28)    0.3477
  piroxicam                                      1.59                         (1.03--2.44)    0.0346
  indometacin                                    1.04                         (0.65--1.68)    0.8585
  flubiprofen                                    1.15                         (0.75--1.76)    0.5224
  sulindac                                       1.59                         (1.03--2.45)    0.0367
  **Comorbidity**                                                                             
  Acute myocardial infarction                    0.54                         (0.11--2.71)    0.4517
  Congestive heart failure                       0.20                         (0.07--0.61)    0.0048
  Cerebral vascular accident                     0.85                         (0.52--1.40)    0.5339
  Dementia                                       1.41                         (0.47--4.22)    0.5425
  Pulmonary disease                              1.09                         (0.79--1.51)    0.6021
  Connective tissue disorder                     3.56                         (0.69--18.29)   0.1276
  Liver disease                                  1.47                         (1.09--2.00)    0.0128
  Diabetes                                       0.75                         (0.52--1.10)    0.1407
  Diabetes complications                         0.89                         (0.41--1.95)    0.7742
  Paraplegia                                     1.59                         (0.24--10.53)   0.6336
  Renal disease                                  0.97                         (0.55--1.71)    0.9150
  Severe liver disease                           0.45                         (0.06--3.45)    0.4414
  Hypertension                                   1.16                         (0.84--1.61)    0.3554
  Hyperlipidemia                                 0.78                         (0.55--1.11)    0.1668
  **Medications use in the baseline period**                                                  
  Antiplatelet                                   1.35                         (0.78--2.35)    0.2802
  Anti-coagulants                                2.22                         (0.14--35.03)   0.5703
  ACEI/ARB                                       0.89                         (0.60--1.34)    0.5849
  SSRIs                                          0.87                         (0.13--5.73)    0.8878
  **Concomitant medications during follow up**                                                
  PPIs                                           1.13                         (0.89--1.44)    0.3022
  H2RA                                           1.85                         (1.47--2.32)    \<0.0001
  Antiplatelet                                   0.65                         (0.41--1.03)    0.0688
  Anti-coagulants                                4.21                         (1.21--14.68)   0.0242
  Cerenin^®^                                     1.08                         (0.40--2.91)    0.8794
  Aspirin                                        1.30                         (0.76--2.23)    0.3382
  SSRIs                                          0.63                         (0.35--1.15)    0.1320

In the models comparing cDDD \> 0 to cDDD = 0, primary cohort: aOR = 1.69 (1.45--1.96), *p* \< 0.0001; matched cohort: aOR = 1.34 (1.10--1.64), *p* = 0.004. Abbreviations: PUD, peptic ulcer disease; NSAIDs, non--steroidal anti-inflammatory drugs; cDDD, cumulative defined daily doses; HP, *Helicobacter pylori*; ACEI/ARB, angiotension-converting enzyme inhibitor/angiotension receptor blocker, PPIs, proton pump inhibitors; H2RA, H2 receptor antagonists; Cerenin^®^, Ginkgo biloba leaves extract; SSRIs, selective serotonin reuptake inhibitors; aOR, adjusted odds ratio; CI, confidence interval.
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###### 

Factors associated with recurrent PUD occurrence between with and without *H pylori* therapy groups in the matched case-control groups.

                                                 *H pylori* Therapy   Without *H pylori* Therapy                                   
  ---------------------------------------------- -------------------- ---------------------------- -------- ------ --------------- ----------
  NSAID use                                                                                                                        
  cDDD \> 0 (ref:DDD = 0)                        1.09                 (0.43--2.77)                 0.8490   1.31   (1.08--1.59)    0.0068
  **NSAID cDDD group (ref: cDDD = 0)**                                                                                             
  cDDD ≤ 28                                                           \-                                    1.24   (1.01--1.52)    0.0424
  28 \< cDDD ≤ 84                                                     \-                                    1.47   (1.11--1.94)    0.0074
  84 \< cDDD                                                          \-                                    1.64   (1.10--2.45)    0.0152
  **Comorbidity**                                                                                                                  
  Acute myocardial infarction                                         \-                                    0.48   (0.10--2.32)    0.3591
  Congestive heart failure                                            \-                                    0.23   (0.08--0.71)    0.0104
  Cerebral vascular accident                     0.52                 (0.06--4.75)                 0.5597   0.83   (0.50--1.39)    0.4737
  Dementia                                                            \-                                    1.26   (0.42--3.74)    0.6772
  Pulmonary disease                              2.57                 (0.28--23.39)                0.4030   0.99   (0.72--1.36)    0.9463
  Connective tissue disorder                                          \-                                    3.31   (0.67--16.41)   0.1420
  Liver disease                                  3.84                 (0.43--34.17)                0.2283   1.50   (1.11--2.02)    0.0083
  Diabetes                                       0.72                 (0.13--4.06)                 0.7049   0.80   (0.55--1.17)    0.2567
  Diabetes complications                                              \-                                    0.85   (0.39--1.88)    0.6929
  Paraplegia                                                          \-                                    1.12   (0.17--7.36)    0.9042
  Renal disease                                                       \-                                    0.86   (0.49--1.51)    0.6063
  Severe liver disease                                                \-                                    0.55   (0.07--4.24)    0.5704
  Hypertension                                   0.67                 (0.15--3.01)                 0.6036   1.17   (0.86--1.59)    0.3299
  Hyperlipidemia                                 1.51                 (0.26--8.88)                 0.6470   0.74   (0.53--1.05)    0.0886
  **Medications use in the baseline period**                                                                                       
  Antiplatelet                                   0.79                 (0.11--5.62)                 0.8136   1.40   (0.80--2.45)    0.2390
  Anti-coagulants                                                     \-                                    0.64   (0.05--9.04)    0.7416
  ACEI/ARB                                       1.57                 (0.23--10.80)                0.6474   0.87   (0.59--1.30)    0.5029
  SSRIs                                                               \-                                    0.87   (0.14--5.45)    0.8850
  **Concomitant medications during follow up**                                                                                     
  PPIs                                           0.38                 (0.17--0.86)                 0.0199   1.24   (0.98--1.58)    0.0735
  H2RA                                           1.89                 (0.70--5.09)                 0.2066   1.74   (1.39--2.18)    \<0.0001
  Anti-platelet agents                           2.98                 (0.55--16.11)                0.2041   0.65   (0.41--1.02)    0.0598
  Anti-coagulants                                                     \-                                    6.34   (1.59--25.32)   0.0089
  Cerenin^®^                                                          \-                                    0.91   (0.33--2.50)    0.8529
  Aspirin                                                             \-                                    1.17   (0.68--2.03)    0.5663
  SSRIs                                                               \-                                    0.59   (0.32--1.08)    0.0882

"-": Numbers of event was too small in the variable group to calibrate odds ratio. Abbreviations: PUD, peptic ulcer disease; NSAIDs, non-steroidal anti-inflammatory drugs; cDDD, cumulative defined daily doses; HP, *Helicobacter pylori*; ACEI/ARB, angiotension-converting enzyme inhibitor/angiotension receptor blocker, PPIs, proton pump inhibitors; H2RA, H2 receptor antagonists; Cerenin^®^, Ginkgo biloba leaves extract; SSRIs, selective serotonin reuptake inhibitors; aOR, adjusted odds ratio; CI, confidence interval.
